Literature DB >> 21975290

Intraductal papillary mucinous neoplasm of the pancreas: associated cancers, family history, genetic predisposition?

Nir Lubezky1, Menahem Ben-Haim, Guy Lahat, Sylvia Marmor, Irit Solar, Eli Brazowski, Richard Nackache, Joseph M Klausner.   

Abstract

BACKGROUND: High rates of extrapancreatic malignancies (EPM) have been observed in patients with intraductal papillary mucinous neoplasm (IPMN). IPMN in patients with familial pancreatic cancer have also been reported. Our purpose was to evaluate the association of IPMN with EPM, malignancies in family members, and germline BRCA1 and BRCA2 mutations.
METHODS: Using retrospective analysis on prospectively collected data from 82 patients with IPMN and direct contact for familial cancer history, data were compared with those of 150 patients with pancreatic ductal adenocarcinoma (PDAC). The common germline mutations in the BRCA1 and BRCA2 genes were evaluated on available IPMN patients.
RESULTS: EPM rates were greater in IPMN than PDAC patients (P = .002). Malignancies in first-degree relatives, specifically pancreatic cancer, were more common among IPMN than PDAC patients (P = .028). IPMN patients with EPM had high rates of relatives with colorectal cancer (31%). Two of the 51 genetically tested patients (4%) were BRCA2 mutation carriers, and both had first-degree relatives with pancreatic cancer. One patient fulfilled the Amsterdam criteria for hereditary nonpolyposis colon cancer; however, the neoplasm was microsatellite stable.
CONCLUSION: Our results demonstrated high rates of EPM among IPMN patients. There was an increased rate of cancer in families of IPMN patients, specifically pancreatic cancer. A high rate of colorectal cancer in families of IPMN patients who have EPM was also observed. These findings suggest a genetic component in the pathogenesis of IPMN. Possible genetic changes include BRCA2 mutations, which are found in 25% of IPMN patients with a family history of pancreatic cancer.
Copyright © 2012 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21975290     DOI: 10.1016/j.surg.2011.06.036

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  10 in total

1.  Prevalence of Germline Mutations Associated With Cancer Risk in Patients With Intraductal Papillary Mucinous Neoplasms.

Authors:  Michael Skaro; Neha Nanda; Christian Gauthier; Matthäus Felsenstein; Zhengdong Jiang; Miaozhen Qiu; Koji Shindo; Jun Yu; Danielle Hutchings; Ammar A Javed; Ross Beckman; Jin He; Christopher L Wolfgang; Elizabeth Thompson; Ralph H Hruban; Alison P Klein; Michael Goggins; Laura D Wood; Nicholas J Roberts
Journal:  Gastroenterology       Date:  2019-02-01       Impact factor: 22.682

Review 2.  Increased risk of second malignancy in pancreatic intraductal papillary mucinous tumors: Review of the literature.

Authors:  Gian Luca Baiocchi; Sarah Molfino; Barbara Frittoli; Graziella Pigozzi; Federico Gheza; Giacomo Gaverini; Antonio Tarasconi; Chiara Ricci; Francesco Bertagna; Luigi Grazioli; Guido A M Tiberio; Nazario Portolani
Journal:  World J Gastroenterol       Date:  2015-06-21       Impact factor: 5.742

3.  A Female With Synchronous Multiple Primary Malignant Tumors in the Esophagogastric Junction, Duodenum and Pancreas: Case Report and Review of the Literature.

Authors:  Yongxing Du; Yunjie Duan; Lipeng Zhang; Zongting Gu; Xiaohao Zheng; Zongze Li; Chengfeng Wang
Journal:  Front Oncol       Date:  2022-05-30       Impact factor: 5.738

4.  Pancreatic intraductal papillary mucinous neoplasm in a patient with Lynch syndrome.

Authors:  Meghan R Flanagan; Arjun Jayaraj; Wei Xiong; Matthew M Yeh; Wendy H Raskind; Venu G Pillarisetty
Journal:  World J Gastroenterol       Date:  2015-03-07       Impact factor: 5.742

Review 5.  Intraductal papillary mucinous neoplasm of the pancreas: an update.

Authors:  Shu-Yuan Xiao
Journal:  Scientifica (Cairo)       Date:  2012-11-28

6.  Characteristics and Clinical Outcomes of Individuals at High Risk for Pancreatic Cancer: A Descriptive Analysis from a Comprehensive Cancer Center.

Authors:  Griffin P J McNamara; Karla N Ali; Shraddha Vyas; Tri Huynh; Monica Nyland; Deanna Almanza; Christine Laronga; Jason Klapman; Jennifer B Permuth
Journal:  Gastrointest Disord (Basel)       Date:  2018-11-01

Review 7.  Talking Genes in Breast and Pancreatic Malignancies.

Authors:  Mary Barbara; Adrianne Tsen; Laura Tenner; Laura Rosenkranz
Journal:  Mater Sociomed       Date:  2019-06

8.  Synchronous double primary malignancies of the pancreatic body and extrahepatic bile duct treated with pancreatoduodenectomy and splenic artery resection following neoadjuvant chemotherapy with gemcitabine plus nab-paclitaxel: a case report.

Authors:  Takahiro Murokawa; Takehiro Okabayashi; Kenta Sui; Motoyasu Tabuchi; Jun Iwata
Journal:  Surg Case Rep       Date:  2022-02-16

Review 9.  Cyst Features and Risk of Malignancy in Intraductal Papillary Mucinous Neoplasms of the Pancreas: Imaging and Pathology.

Authors:  Lars Grenacher; Albert Strauß; Frank Bergmann; Matthew Birdsey; Julia Mayerle
Journal:  Viszeralmedizin       Date:  2015-02

10.  A case of successful conversion surgery for locally advanced pancreatic cancer with synchronous triple cancer of the lung and esophagus: a case report.

Authors:  Junya Mita; Tomohiro Iguchi; Norifumi Iseda; Kazuki Takada; Kosuke Hirose; Naoko Miura; Takuya Honboh; Yasunori Emi; Tetsuro Akashi; Seiya Kato; Noriaki Sadanaga; Hiroshi Matsuura
Journal:  Surg Case Rep       Date:  2022-01-24
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.